Industry Insights
Industry Insights
Original, structured takes on the topics we track — brain–computer interfaces, artificial hearts, medical polymers and silicone, regulation and market — always circling back to one question: how to choose materials and supply.
10Brain–Computer Interface
BCI in 2026: technology paths, the global landscape and China's rise
BCI is moving from validation to scale, US–China dual-core, with long-term implant bottlenecks s
Brain–spine interfaces heat up: the 'neural bridge' route and a 300M+ round
Unlike 'function replacement', a brain-spine interface rebuilds the brain–cord pathway so patien
Map of China's core BCI companies: three tiers and technology routes
From a non-invasive leader to an invasive twin-engine, China now has the world's first approved
China prices BCI: invasive implantation fee RMB 6,000–6,600 per case
Approval–coding–pricing in quick succession solves the 'approved but un-billable' problem first
BCI industrialization accelerates: from 'concept race' to 'execution'
High-channel implant trials, a quarter beating last year's funding, a policy mention — competiti
BCI rallying call: policy, capital and commerce hit the accelerator together
A 100B fund, a full-chain lab, big-tech stakes, insurance coverage — triple resonance, but the r
What decides BCI: electrodes, encapsulation and systems engineering
Competition shifts from decoding to hardware — electrode flexibility and long-term encapsulation
Xiangyu Medical bets RMB1.37bn on non-invasive BCI rehab
A billion-yuan placement wires EEG acquisition, AI decoding and rehab hardware into one loop for
BCI value chain: the 'resonance' of tech and commercialization
Under policy + tech + scenarios, invasive competes on timeline, cost and barriers; non-invasive
May 2026: a wave of BCI funding starts betting on 'system engineering'
Several rounds closed in half a month, and the through-line is clear: competition moved from alg
8Artificial Heart & Circulatory Support
Carmat Aeson total artificial heart: design and materials of the EU's only commercial TAH
Full biventricular replacement, hydraulic pulsation, a bio-mimetic blood interface — TAH pushes
Percutaneous RVAD enters the 'green channel': the overlooked right heart and a harder materials problem
Heart failure isn't only the left heart — RVADs lagged partly because venous blood demands highe
China's maglev artificial heart: from first implant to the global high-end market
From a 2017 first implant to over half its 2025 revenue overseas, the maglev artificial heart ep
The artificial-heart 'first IPO' race: revenue up three years, yet years of losses
Revenue from RMB 50M to 213M, yet over RMB 1B of losses in three years — early-commercialization
Capital bets on the artificial heart: the 'crown jewel' and the first-IPO race
Valuation up ~6x in three years and strategic stakes pouring in — the artificial heart is capita
The economics of the artificial heart: ~RMB 600k price, unit cost and the 'bridge' debate
1,300+ implants and 45%+ 2024 share, yet artificial hearts are mostly a 'bridge' before transpla
'Rocket Heart 2.0' HeartCon II: design highlights of a 75-gram maglev blood pump
75g pump, no in-pump sensors, up to 10 L/min — a domestic maglev pump sets a new bar.
China's artificial hearts: implantable + percutaneous, and how materials gatekeep
The field is stretching from end-stage therapy to the full heart-failure course; blood contact a
11Medical Polymers & Silicone
Silicone, silicone oil, silicone resin: how they relate, in 3 minutes
All share the 'siloxane' surname — they differ only in structure, crosslinking and form. One fam
Medical polymers: which biocompatibility tests do you actually need?
Don't pick tests by copying rivals — choose by contact site × duration, which is the ISO 10993 l
Biodegradable medical implants: materials, degradation and validation boundaries
Biodegradable does not mean automatically safer; intended function, degradation, functional rete
Putting the gas outlet on the blade: an engineering take on gas–liquid mixing
Put bubble generation and dispersion in one energy-input zone — a mixing trick for hard-to-dispe
From R&D to startup: what a complete chemical process package should contain
A process package answers 'where the tech comes from' and 'how to build the plant' — the enginee
Choosing medical silicone: LSR vs HCR
In short: high-volume thin-wall precision parts call for LSR; extruded tubing/sheeting/thick sec
Restricted vs unrestricted: how implant-grade medical silicone is split and chosen
It comes down to contact duration: <=29 days looks at restricted; >29-day long-term implants nee
Choosing a silicone cure system: platinum / peroxide / condensation
Thick, clean, low-shrink parts favor platinum addition; extruded tubing often uses peroxide; one
Dow's $100M specialty-silicone push: what it means for medical-silicone supply
The expansion centers on LSR, electronic silicones and thermal management for transport/electron
Bluestar Silicones relaunches: reading silicone consolidation as a device buyer
Global silicone is concentrating into a few suppliers. For device makers, the thing to watch is
Sutureless nerve repair: a new route that 'couples' tissue with materials
From a 'suture era' to a 'material-coupled era', programmable polymer aims to change the surgica
9Regulatory · Registration · Quality
FDA UDI: labeler, DI/PI, GUDID and direct-marking boundaries
Separate who is responsible, what appears on labels, what the database stores, and when direct m
Reading ISO 13485 through PDCA: the logic behind the quality system
Treat the system as paperwork and you get a 'two-skins' gap; through PDCA it's really consistent
Medical-device biological evaluation: a risk-based evidence route
Endpoint tables are an evaluation framework, not a test checklist; address each endpoint with ev
Medical-device 'product realization' elements: the quality chain from design to release
Product realization turns quality into action: plan→design→purchase→produce→measure, interlocked
How to compile a device registration dossier: structure, key points and requirements
Break hundreds of pages into modules: summary, studies, labeling, QMS — a clear backbone avoids
How few people can a medical-device company have? Start with GMP key roles
Not 'as few as possible' — GMP needs key roles filled, and quality and production heads can't do
China's 'AI+Manufacturing' plan names BCI and surgical robots
From upstream smart chips to downstream surgical robots and diagnostics, policy hits the acceler
10 core medical-device terms every newcomer should know, explained
510(k)/PMA/NMPA/CE/IVD/SaMD/CAPA/GCP/QMS/UDI: 10 keys to the industry's jargon.
BOM and multi-level BOM, explained: how a bill of materials is built
A BOM is the product's 'recipe'; a multi-level BOM breaks the finished good down to raw material
12Market · Trade · Industry
Is China a medical-device exporter or importer? Finding position from trade data (1)
The $59B you find is a distorted basis; narrowly, 2024 exports were ~$18B — closer to balance.
China's core medical-instrument exports: HS 9018 vs Germany and the US (2015–2024)
On one HS 9018 basis, China's 2015–2024 export CAGR was 8.52%. This is not all medical devices o
How did the global device trade market form? Finding position from trade data (3)
The US export/output ratio rose from 10% to 40%+ (1990→2016) — a microcosm of global device trad
How big is US medical-device output? Finding position from trade data (4)
Backward ~$169B, forward ~$173B — 2024 US device output is ~$170B.
China's device output and domestic demand: finding position from trade data (5, finale)
Output ~$193B, ~32,800 firms, demand ~$178B — bases differ, but the method travels.
Across 414 innovative-device certificates, which lanes are getting 'crowded'?
About 2/3 fall in the last 3.5 years; innovation moves from single products to complex systems a
China medical-device market in numbers: size, exports, firms and localization
RMB 1.22T market, steady export growth, 35k firms, 95% consumable localization — the macro pictu
MedTech talent supply & demand: behind a trillion-yuan market
Market over a trillion, firms over a million — yet 'big but not strong'; what is scarce is R&D a
Quantum in healthcare: next-stage value and the prerequisites
A frontier-trend read: quantum enables biological simulation, faster drug discovery and data pro
A map of medical-device segments: where silicone lands, materials-first
Split devices into four blocks, then mark where medical silicone and polymers land — selection a
Lepu's transformation: outside the VBP wall, funding innovation with cash flow
VBP squeezes low-barrier lines, so a leader redirects cardiovascular cash flow into self-pay, se
China begins national VBP groundwork for digestive intervention devices
Esophageal, intestinal and biliary stents enter historical-procurement reporting — the precursor
5Device Segments & Clinical
The century-long catheter infection war: Foley design, CAUTI and the coating path
The same tube saves and infects — to cut CAUTI, materials and coatings are unavoidable battlegro
Nystagmus device approved: after the breakthrough, commercialization begins
Striking data (gaze +587%, tremor -84%), but finding patients, training surgeons and who pays is
A double breakthrough in minimally invasive glaucoma care: RF ablation and suprachoroidal drainage
Multi-mechanism RF ablation + suprachoroidal drainage — domestic ophthalmic devices reach the gl
AI medical devices 2025: a RMB52.5bn market and the 'screen-diagnose-treat-manage' upgrade
Imaging and software AI devices scale fast, but hardware raw materials still dominate cost — ups
Lixiao tibial neurostimulation: what is reported, and what still needs verification
Company-source reporting is separated from implant-packaging research, wireless guidance and pro
4Industry Bulletin Digest
Polymer Medical Device Bulletin 2025 Issue 1 digest: regulatory reform and annual data
No. 53 reform, the 2024 registration report, 95% consumable localization — the issue's citable p
Polymer Medical Device Bulletin 2025 Issue 3 digest: procurement changes and EU exports
Procurement's 'eight changes' move beyond lowest price; H1 EU exports topped USD 5B — one issue
Polymer Medical Device Bulletin 2025 Issue 4 digest: device law and a materials challenge
Device-law legislation, a materials 'open competition', a RMB 1.22T market — year-end policy and
Polymer Medical Device Bulletin 2026 Issue 1 digest: annual highlights and UDI progress
2025's top-10 regulatory highlights, the device law on the agenda, follow-on UDI — the year's op